Phase-III-Studie zu Carboplatin-Paclitaxel/Nab-Paclitaxel (Chemo) mit oder ohne Pembrolizumab (Pembro) für Patienten (PTS) mit metastasiertem squamösen nicht-kleinzelligem Lungenkrebs

ASCO Annual Meeting 2018 – Abstract: No. 7010, Paz-Ares, LG et al.: KEYNOTE-407-Studie

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

 

 

Conclusion:

“Adding pembro almost doubled the ORR of chemo for pts with untreated metastatic sq NSCLC. Pembro + chemo has a tolerable safety profile. Results from a second interim analysis may be available prior to the meeting.”

 

Clinical trial information: NCT02775435

 

Quelle:

Paz-Ares, LG et al. ASCO 2018, Clinical Science Symposium

J Clin Oncol 36, 2018 (suppl; abstr 105)

https://meetinglibrary.asco.org/record/161511/abstract